# Claret Capital Partners

> Claret Capital Partners is a VC fund backing Software. See 111 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 111
- Last investment: Aug 2026
- Lead investor: 26%
- Fund size: $348M
- Last fund: Aug 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/claret-capital-partners/
- Website: https://www.claret-capital.com/

Claret Capital Partners is a VC fund in London focused on Software and Information Technology. Claret Capital provides specialty debt financing to European growth businesses, predominantly in the technology, life sciences and environmental sectors. Typical loan sizes range from €1M-€40M with the flexibility to do larger transactions opportunistically.They look for investment opportunities in high growth business with proven managementteams in need of capital to fuel organic growth, acquisitions, equipment purchases, bridge loans and various forms of recapitalization.

## Contacts

5 contacts available for Claret Capital Partners. Shizune tracks 7 team members at Claret Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/harbert-european-growth-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Post-IPO Debt | $9.2M–$165M |
| Debt Financing | $2M–$24M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 32 | 29% |
| Information Technology | 16 | 14% |
| Mobile | 13 | 12% |
| E-Commerce | 13 | 12% |
| Health Care | 11 | 10% |

180 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Debt Financing | 77 | 69% |
| Funding Round | 7 | 6% |
| Post-IPO Debt | 6 | 5% |
| Venture - Series Unknown | 6 | 5% |
| Series A | 3 | 3% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 26 | 23% |
| Germany | 22 | 20% |
| United States | 17 | 15% |
| Ireland | 11 | 10% |
| France | 9 | 8% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bryan McLoughlin | Vice President | 0 | https://shizune.co/investors/profile/bryan-mcloughlin |
| David Bateman | Managing Partner | 1 | https://shizune.co/investors/profile/david-bateman-3ddb |
| Fahad Khan | Vice President | 0 | https://shizune.co/investors/profile/fahad-khan-96b7 |
| Jerome Fonteneau | Portfolio and Operations Director | 0 | https://shizune.co/investors/profile/jerome-fonteneau |
| Johan Kampe | Senior Managing Director | 0 | https://shizune.co/investors/profile/johan-kampe |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Affluent Medical | Affluent Medical develops innovative new-generation mini-invasive implants to restore essential physiological functions in these areas: - Kardiozis aims to prevent endoleaks and risks of recurrence of the abdominal aortic aneurysm allowing patients to live more serenely facing an unpredictable risk of breakage; - Kalios and Epygon aim to providemore physiological surgical treatments for the repair or replacement of the mitral valve of the heart. Kalios can treat residual post-operative leakage and recurrent mitral insufficiency without having to reoperate patients. Epygon is today the only developing transcatheter valve to restore natural blood flow and safeguard the left ventricle. - Finally, Artus is the first electronically activatable artificial sphincter to treat stress urinary incontinence in men and women. | $11.5M | Post-IPO Debt | Aug 06, 2026 |  |
| Inventiva Pharma | Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $151.5M | Post-IPO Debt | Jun 01, 2026 |  |
| Paysend | PaySend is a financial technology platform that solves the universal problem to securely enable any bank card (Visa or MasterCard) to send and receive money worldwide. It is a next-generation money transfer platform allowing its users to send funds from card to card from 40 to over 60 countries. | $25M | Venture - Series Unknown | Mar 31, 2026 |  |
| Wellster Healthtech Group | Wellster is the go-to solution for everyday consumer health. It builds digital clinics along the lifecycle of next gen. health consumers. | $11.5M | Debt Financing | Mar 23, 2026 |  |
| Cinclus Pharma | Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $9.2M | Post-IPO Debt | Mar 13, 2026 |  |
| Deciphex | Founded in 2017, Deciphex aims to transform diagnostic workflows through AI-powered digital pathology to improve patient outcomes worldwide. Its two flagship platforms target distinct markets: Diagnexia connects global subspecialty pathologists for rapid diagnostics and backlog reduction, while Patholytix accelerates drug development throughoptimized preclinical safety assessments. By automating routine tasks, these platforms enable pathologists to focus on complex cases while delivering faster, more reliable diagnoses. Through this combination of AI innovation and clinical expertise, Deciphex is advancing both healthcare delivery and therapeutic development. | $17.6M | Debt Financing | Oct 02, 2025 |  |
| Mindler | Most people suffer at some point during the life of mental illness. Whether it comes to periods of stress, drowsiness or worry that does not disappear by itself, a professional contact can be an effective way back and prevent negative development. They started Mindler with the vision that everyone should have the opportunity to meet a psychologiston equal terms, no matter where you live or what conditions you have. Digital technology and leading psychological skills are our model for increasing access to effective treatment of mental health and for people in our country to get the best help they need. | $11.6M | Debt Financing | Aug 27, 2025 |  |
| VIOTAS | VIOTAS is an electric utility company that provides electric power and smart grid technology for commercial or industrial facilities. | $11.3M | Debt Financing | May 22, 2025 |  |
| Cardiac Dimensions | Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M | Series E | Mar 20, 2025 |  |
| quantilope | quantilope's platform automates high-level research methodologies including Conjoint, MaxDiff, Implicit Association Tests, and more, offering tools and customization to answer questions from ideation through development, launch, and tracking of your products, ads, and concepts. quantilope is an end-to-end platform, mapping the entire marketresearch process from the research question to the questionnaire design, professional panel management, in-depth analysis, and data visualization. |  | Debt Financing | Dec 20, 2024 |  |

10 of 111 investments shown.

## Co-investors
- [EQT Ventures](https://shizune.co/investors/profile/eqtventures) — VC Fund, 2 deals together
- [ETF Partners](https://shizune.co/investors/profile/etf-partners) — VC Fund, 2 deals together
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund, 2 deals together
- [Heal Capital](https://shizune.co/investors/profile/heal-capital) — VC Fund, 2 deals together
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund, 2 deals together
- [Idinvest Partners](https://shizune.co/investors/profile/idinvest-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Development Bank of Wales](https://shizune.co/investors/profile/development-bank-of-wales) — VC Fund
- [The FSE Group](https://shizune.co/investors/profile/finance-south-east) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)
- [Health Care VC Funds in Ireland](https://shizune.co/investors/health-care-vc-funds-ireland)
- [Hardware VC Funds in Ireland](https://shizune.co/investors/hardware-vc-funds-ireland)
- [Hardware Investors in Ireland](https://shizune.co/investors/hardware-investors-ireland)
- [Travel Investors in Spain](https://shizune.co/investors/travel-investors-spain)
- [Travel VC Funds in Spain](https://shizune.co/investors/travel-vc-funds-spain)

## FAQ

### What does Claret Capital Partners invest in?

Claret Capital Partners invests primarily in Software, Information Technology and Mobile startups, most often at Debt Financing and Funding Round stage. Most of the 111 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Claret Capital Partners's check size?

Claret Capital Partners typically joins rounds of $9.2M–$165M at Post-IPO Debt and $2M–$24M at Debt Financing. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Claret Capital Partners participates in.

### How do I contact Claret Capital Partners?

Public channels for Claret Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Claret Capital Partners?

The team at Claret Capital Partners includes Bryan McLoughlin (Vice President), David Bateman (Managing Partner) and Fahad Khan (Vice President), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co